ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2013

Nurse Practitioner

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,467Medicare Part D Prescriptions Filled, Including Refills

Rank: 1 out of 269

$1.37M Total Retail Price of All Prescriptions

Rank: 2 out of 269

423 Patients Receiving at Least One Drug in Part D
15% Patients 65 Years and Older
86% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg 81928cdb0ebe162ff75cf405bfacadd396bf3ec84bc467b6f3e612dd63daa776 Average for
this specialty
in Minnesota
Lower avg 72b1978e1dcc0b845f89d17d692cfff7aeaf8d8bce70310d8bfc535db2daf62a

Schedule Two
Controlled Substances

18% of this provider’s 423 patients filled at least one prescription for a schedule two drug, compared to an average of 12%.

Schedule Three
Controlled Substances

N/A

Brand Name Drugs*

19% of this provider’s prescriptions were for brand-name drugs, compared to an average of 20%.

Prescription Price

$119 was the average price of a prescription from this provider, compared to $68 among peers.

Prescriptions per Patient

27 is the average number of prescriptions (including refills) per patient, compared to an average of 10.


This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

B

A benzodiazepine, or tranquilizer. More » The American Geriatrics Society says these drugs increase the risk of cognitive impairment, delirium, falls and fractures in older adults.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled with Refills Prescriptions
to 65+
Patients Recieving this Drug Category For this Prescriber For All Prescribers in
This Specialty in Minnesota
CLONAZEPAM 528 62 86 B 1 40
TRAZODONE HCL 491 15 69 2 28
BUPROPION XL 471 79 64 3 54
ZOLPIDEM TARTRATE 454 42 70 4 41
LORAZEPAM 405 79 76 B 5 23
SERTRALINE HCL 389 54 51 6 20
QUETIAPINE FUMARATE 381 27 53 A 7 31
ALPRAZOLAM 370 47 56 B 8 72
CLOZAPINE 355 0 14 A 9 50
CYMBALTA 345 15 39 10 45
VENLAFAXINE HCL ER 341 75 36 11 48
RISPERIDONE 331 74 39 A 12 46
LAMOTRIGINE 307 32 47 13 55
ABILIFY 307 20 43 A 13 76
ESCITALOPRAM OXALATE 239 21 32 15 87
BUSPIRONE HCL 238 28 30 16 89
CITALOPRAM HBR 219 29 35 17 18
FLUOXETINE HCL 198 30 28 18 75
DIVALPROEX SODIUM ER 185 13 24 19 85
MIRTAZAPINE 185 52 29 19 27
DIAZEPAM 166 19 26 B 21 111
AMPHETAMINE SALT COMBO 165 0 27 S2 22 97
DOXEPIN HCL 163 <11 23 23 113
OLANZAPINE 160 <11 22 A 24 74
TOPIRAMATE 159 12 25 25 78
HYDROXYZINE PAMOATE 148 14 31 R 26 117
DEXTROAMPHETAMINE-AMPHETAMINE 139 0 18 S2 27 123
LITHIUM CARBONATE 135 <11 16 28 126
OXCARBAZEPINE 135 <11 15 28 126
ZIPRASIDONE HCL 132 <11 15 A 30 128
BENZTROPINE MESYLATE 129 19 21 R 31 98
GABAPENTIN 124 27 18 32 14
BUPROPION HCL SR 119 <11 17 33 137
ZALEPLON 107 <11 21 34 143
TEMAZEPAM 106 30 25 B 35 145
PAROXETINE HCL 105 11 13 36 51
PRAZOSIN HCL 101 0 18 37 151
STRATTERA 91 <11 <11 10 38 157
INVEGA SUSTENNA 91 <11 <11 A 38 157
DEXTROAMPHETAMINE SULFATE 90 <11 15 S2 40 159
RISPERDAL CONSTA 87 <11 <11 A 41 160
TRIHEXYPHENIDYL HCL 85 <11 <11 R 42 162
VIIBRYD 84 13 14 43 164
DIVALPROEX SODIUM 82 13 11 44 68
THIOTHIXENE 69 <11 <11 A 45 177
FAZACLO 68 <11 <11 A 46 178
PERPHENAZINE 64 <11 <11 A 47 186
PRISTIQ ER 60 <11 <11 48 189
METHYLPHENIDATE ER 57 <11 13 S2 49 204
FLUVOXAMINE MALEATE 55 <11 <11 50 207
LUNESTA 55 0 11 50 207
SEROQUEL XR 55 <11 <11 A 50 207
FANAPT 50 <11 <11 A 53 223
AMITRIPTYLINE HCL 50 <11 <11 R 53 143
About This Data

Prescribing data from Medicare’s prescription drug benefit, known as Part D, was compiled and released by the Centers for Medicare and Medicaid Services, the federal agency that oversees the program. ProPublica combined that data with additional information released by CMS. The data for 2013 includes nearly 1.4 billion prescriptions written by 1.3 million doctors, nurses and other providers. This database lists about 410,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths of these prescriptions went to patients 65 and older; the rest were for disabled patients Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to checkup@propublica.org and we will update your information. If you have other questions about this data, send a note to checkup@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Dec. 30, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.